INEOS Automotive CEO on navigating evolving tariff landscape
Lynn Calder, INEOS Automotive CEO, joins Market Catalysts with Julie Hyman to discuss how the company is navigating trade tensions, pricing caps, and plans to expand its lineup with a hybrid range extender.
To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Rolls-Royce CFO talks profit jump, engine upgrades, & growth
Shares of UK-based aerospace and defense manufacturer Rolls-Royce Holdings (RR.L) hit a record after a jump in first-half profit, driven by gains in its civil aerospace, defense, and energy divisions. Helen McCabe, CFO of Rolls-Royce, joins Market Catalysts to discuss progress on engine durability and how its turnaround plan is paying off. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Yahoo
Consumers are focused on value right now: What earnings tell us
This earnings season has revealed a big trend in consumer behavior: searching for lower prices. Yahoo Finance Senior Reporter Brooke DiPalma joins Market Catalysts with Julie Hyman to discuss the details. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. One theme emerging this earnings season from companies selling everything from appliances to cleaning products, consumers are looking for lower prices. Yahoo Finance senior reporter Brooke DiPalma joins me now. Brooke, of course, you closely watch these companies. So what are they telling us about the state of the consumer? Julie, consumers are extremely price conscious nowadays, as they think about and navigate this uncertainty within the environment when it comes to tariffs, those elevated interest rates, they're looking ultimately for the best deal wherever they can. And that's what we heard as well from Kraft Heinz out this morning, where we did see a volume decline, but they did say that they're leaning into this idea of that value conscious consumer. They also said that they're being mindful about the current consumer situation when they do have to take pricing in order to offset tariffs. But this is not something new from Kraft Heinz that we heard this morning. We've been hearing this over the course of these quarterly results from Q2, as well, from food and beverage giants like Coca-Cola, as well as PepsiCo. Coca-Cola's CFO told me last week that the lower income consumer remains under pressure, but he went on to say that part of what they continue to be very focused on is ensuring that they offer even more affordable options as they keep this consumer environment in mind. PepsiCo also saying with their earnings call that better entry points and value has been successful for the company in order to offset this fear, this worry that consumers have, and then mindfulness that consumers have heading into the grocery store. But let's move away from pantry. It's not just that. If you go into your cleaning closet as well, chances are you might have grabbed a cheaper alternative, and that's exactly what we heard from PNG CEO, John Moller, on Tuesday. Take a listen. We are seeing modest trade down within our branded portfolio. Uh so within uh the different tide offerings, there are some that are are more premium than others, and we are seeing some trade down there. We're also seeing some trade down to brands uh that you mentioned like Gain. We are not seeing any trade down as of yet to uh private label. So maybe we're putting aside those tide pods and we're going for the regular Gain detergent instead. But when you think about the households at large, of course, it's not just these small goods that we're grabbing in the grocery store. American consumers are also being mindful when they have to replace certain items, like say, their KitchenAid mixer, or their Whirlpool Whirlpool kitchen appliances, their Maytag kitchen appliances. We heard from Whirlpool as well behind all those big ticket appliances that consumers there are being mindful. The CEO there, Mark Bitzer, saying, we continue to see consumers choosing to mix into lower end products. And so, all in all, Julie, we continue to hear from these executives that consumers are being extremely price conscious. They're really looking for the best deal here. And that's what we really heard going into this season. That's certainly playing out, but all eyes will be on how this is playing out for those big box retailers that we'll hear from in mid-August. Yeah, that's the next shoe, I guess. Brooke, thank you so much.
Yahoo
3 days ago
- Yahoo
AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio
